Items tagged with Drug-sensitive TB
New clinical practice guidelines: Treatment of drug-susceptible TB (post with simple image)
Jointly developed by the American Thoracic Society, U.S. Centers for Disease Control and Prevention and Infectious Diseases Society of America.
Are pretomanid-containing regimens for TB a victory or a victory narrative? (post with simple image)
"Given the evidence base available to us currently, can we claim pretomanid a victory? We think more research is needed before pretomanid can be celebrated as a promising treatment for people with tuberculosis."
Landmark TB trial identifies shorter-course treatment regimen (post with simple image)
Landmark phase III trial shows that the shorter regimen containing rifapentine and moxifloxacin can safely and effectively cure TB in four months.
SHINE trial on shorter treatment for children with minimal TB (post with simple image)
TB treatment can be shortened from six to four months in 80% of children.
Landmark TB trials results published in New England Journal of Medicine (post with simple image)
A shorter regimen containing rifapentine and moxifloxacin can cure TB in four months.
An Activist’s Guide to Shorter Treatment for Drug-Sensitive TB (post with simple image)
This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.
Major improvements in quality of life for people with drug-susceptible TB expected following updates in TB treatment regimens (post with simple image)
The updated WHO consolidated guidelines on treatment of drug-susceptible TB include a new recommendation for the use of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin and pyrazinamid.
Response to TB treatment trials results published and presented during the 2022 Union World Conference on Lung Health (post with simple image)
Statement by Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB)
TB Alliance launches five-country Phase 2 clinical trial evaluating next-generation TB drug (post with simple image)
A combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, has the potential to become a 'universal TB regimen', shortening and improving treatment for both drug-sensitive and drug-resistant TB.
Page 5 of 5 · Total posts: 0
←First 4 5